Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648086 | 0.95 | C5AR1 (0.55) | C5AR1PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL651054 | 0.94 | C5AR1 (0.52) | C5AR1PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL648162 | 0.93 | C5AR1 (0.48) | C5AR1PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL648481 | 0.93 | C5AR1 (0.48) | C5AR1PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL650741 | 0.93 | C5AR1 (0.52) | C5AR1PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL651607 | 0.91 | C5AR1 (0.51) | C5AR1PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL652444 | 0.91 | C5AR1 (0.51) | C5AR1MAPTSIRT2GSK3AGSK3B | |
| SCHEMBL649699 | 0.91 | C5AR1 (0.51) | C5AR1PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL5136520 | 0.90 | C5AR1 (0.61) | C5AR1TSHRMAPTSIRT2MEN1 | |
| SCHEMBL651293 | 0.90 | C5AR1 (0.49) | C5AR1PTGDR2CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| CN-101878031-A | The inhibitors of kinases that is used for the treatment of myeloproliferative disease and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC | 2010-11-03 | — | — | CN | disclosed |
| WO-2010078103-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| CN-1744892-A | Breast cancer resistance protein (BCRP) inhibitor | YAKULT HONSHA KK (JP) | 2006-03-08 | — | — | CN | disclosed |
| EP-0390915-A4 | WHOLLY AROMATIC POLYESTERS OF ISOPHTHALIC ACID, TEREPHTHALIC ACID, P-HYDROXYBENZOIC ACID, HYDROQUINONE AND AN ARYLENE DIOL | — | 1992-07-22 | — | — | EP | disclosed |
| EP-0390915-A1 | WHOLLY AROMATIC POLYESTERS OF ISOPHTHALIC ACID, TEREPHTHALIC ACID, p-HYDROXYBENZOIC ACID, HYDROQUINONE AND AN ARYLENE DIOL. | AMOCO CORP (US) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | C5AR1 4453/4885PTGDR2 410/4885CYP2C8 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.